Trial results using preformed HSA-ICG for SLN detection in cervical, vulvar, and breast cancer patients found no significant difference between it and using ICG alone, therefore concluding that administrating ICG-HSA had no advantage over ICG alone [18,19,20]. This evidence concerns the gene ALB and breast carcinoma.